/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR
DISSEMINATION IN THE UNITED
STATES/
LEAMINGTON, ON, Jan. 3, 2018 /CNW/ - Aphria Inc. ("Aphria" or
the "Company") (TSX: APH or USOTCQB: APHQF) is pleased to
announce it has closed its short form prospectus offering, on a
bought deal basis, including the exercise in full of the
underwriters' over-allotment option. A total of
8,363,651 common shares (the "Shares") of the Company
were sold at a price of $13.75 per
Share, for aggregate gross proceeds of $115,000,201 (the "Offering").
The Offering was underwritten by a syndicate of underwriters led by
Clarus Securities Inc. and included AltaCorp Capital Inc., Cormark
Securities Inc., and Canaccord Genuity Corp (collectively, the
"Underwriters").
The net proceeds of the Offering are expected to be used in
connection with international strategic investments, including
direct investment, construction or acquisition of production
facilities in new markets, located in federal legal markets
(specifically excluding the United
States), all related to cannabis production facilities;
strategic investments to enhance the Company's product offerings or
cultivation capabilities; construction or acquisition of domestic
retail facilities for distribution of cannabis under the
Cannabis Act (Canada), in
those provinces which may allow it; construction or acquisition of
domestic production facilities, if required to support
provincialism within the Cannabis Act (Canada); and general corporate purposes.
Until spent by the Company, the net proceeds of the Offering
will be held as cash balances in the Company's bank account or
invested at the discretion of the Company's Board of Directors.
The Shares were offered for sale in each of the provinces of
Canada, other than the Province of
Quebec, by short form prospectus,
and in those jurisdictions outside of Canada and the
United States which were agreed to by the Company and the
Underwriters, where the Shares were issued on a private placement
basis, exempt from any prospectus, registration or other similar
requirements.
This news release does not constitute an offer to sell or a
solicitation of an offer to buy any of the securities of Aphria
Inc. in the United States, nor
shall there be any sale of the securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful. The
securities offered have not been and will not be registered under
the U.S. Securities Act or any U.S. state securities laws and may
not be offered or sold within the United
States or to, or for the account or benefit of, U.S. Persons
unless registered under the U.S. Securities Act and applicable
state securities laws or unless an exemption from such registration
is available.
About Aphria
Aphria Inc., one of Canada's
lowest cost producers, produces, supplies and sells medical
cannabis. Located in Leamington,
Ontario, the greenhouse capital of Canada. Aphria is
truly powered by sunlight, allowing for the most natural growing
conditions available. We are committed to providing
pharma-grade medical cannabis, superior patient care while
balancing patient economics and returns to shareholders.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward-looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "believe", "intend" or the
negative of these terms and similar expressions. Forward-looking
statements in this news release include, but are not limited to,
statements with respect to internal expectations, the use of
proceeds of the Offering and the intended expansion of the
Company's facility and the anticipated timing with respect to such
expansion. Forward-looking statements necessarily involve known and
unknown risks, including, without limitation, risks associated with
general economic conditions; adverse industry events; marketing
costs; loss of markets; future legislative and regulatory
developments involving medical marijuana; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
medical marijuana industry in Canada generally, income tax and regulatory
matters; the ability of Aphria to implement its business
strategies; competition; crop failure; currency and interest rate
fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
SOURCE Aphria Inc.